What is HC Wainwright’s Forecast for SLN FY2024 Earnings?

Silence Therapeutics plc (NASDAQ:SLNFree Report) – Equities research analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Silence Therapeutics in a note issued to investors on Wednesday, January 29th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.73) per share for the year, down from their previous estimate of ($1.60). HC Wainwright currently has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($0.41) EPS.

SLN has been the subject of a number of other reports. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Morgan Stanley reiterated an “overweight” rating and set a $49.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, October 8th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Finally, Chardan Capital reiterated a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a report on Tuesday, December 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Silence Therapeutics has an average rating of “Buy” and a consensus price target of $54.75.

View Our Latest Research Report on Silence Therapeutics

Silence Therapeutics Stock Up 10.9 %

Shares of Silence Therapeutics stock opened at $5.61 on Monday. Silence Therapeutics has a 12-month low of $4.82 and a 12-month high of $27.72. The firm has a market capitalization of $167.90 million, a PE ratio of -3.57 and a beta of 1.08. The stock’s fifty day moving average is $6.52 and its 200-day moving average is $13.52.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors have recently modified their holdings of SLN. Eventide Asset Management LLC bought a new stake in Silence Therapeutics in the third quarter worth approximately $11,635,000. Millennium Management LLC lifted its stake in shares of Silence Therapeutics by 91.2% in the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after purchasing an additional 373,523 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Silence Therapeutics by 219.3% in the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after purchasing an additional 321,300 shares in the last quarter. Janus Henderson Group PLC increased its position in Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after buying an additional 268,250 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

Further Reading

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.